The Nobelpharma auditory system bone-anchored hearing aid: the Edmonton experience.
The unique ability of titanium to osseointegrate has been utilized in clinical practice for bone-anchored hearing aids in Sweden since 1977. The percutaneous design by Nobelpharma has been shown to be useful not only for pure conductive hearing loss but also mixed losses with a bone pure tone average of 45 dB (60 dB with the HC220). We examine our experience, since May 1991, with 15 patients aged 8 to 73 years, including indications, complications, and both objective and subjective results. In addition, we have found the second stage can be successfully completed during the initial anesthetic without the usual delay of 3 months for many patients. We believe the technique for osseointegration is a suitable addition to the armamentarium for the otolaryngologist against hearing loss.
Liepert
D R
DR
Department of Surgery, University of Alberta Hospital, Edmonton.
DiToppa
J C
JC
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004427:Ear Diseases / Q000150:complications* / Q000503:physiopathology; D004867:Equipment Design; D005500:Follow-Up Studies; D006310:Hearing Aids; D006314:Hearing Loss, Conductive / Q000175:diagnosis / Q000209:etiology / Q000534:rehabilitation*; D006801:Humans; D008875:Middle Aged; D011183:Postoperative Complications; D012189:Retrospective Studies; D012882:Skin Tests; D013069:Speech Reception Threshold Test; D011795:Surveys and Questionnaires; D013548:Sweden; D014025:Titanium
D014025:Titanium